Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

BACKGROUND: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature. METHODS: Women with ROC relapsing >6 months after...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, U, Marth, C, Largillier, R, Kaern, J, Brown, C, Heywood, M, Bonaventura, T, Vergote, I, Piccirillo, M C, Fossati, R, Gebski, V, Lauraine, E P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419956/
https://www.ncbi.nlm.nih.gov/pubmed/22836511
http://dx.doi.org/10.1038/bjc.2012.307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419956/
https://www.ncbi.nlm.nih.gov/pubmed/22836511
http://dx.doi.org/10.1038/bjc.2012.307

Ejemplares similares